Viveve Medical (VIVE) Given “Buy” Rating at Ladenburg Thalmann Financial Services

Viveve Medical (NASDAQ:VIVE)‘s stock had its “buy” rating reissued by Ladenburg Thalmann Financial Services in a research note issued on Thursday.

A number of other brokerages have also issued reports on VIVE. Cowen set a $11.00 price target on Viveve Medical and gave the stock a “buy” rating in a research note on Monday, October 23rd. ValuEngine lowered Viveve Medical from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Mizuho reiterated a “buy” rating and issued a $10.00 price target on shares of Viveve Medical in a research note on Friday. Finally, Northland Securities began coverage on Viveve Medical in a research note on Friday. They issued an “outperform” rating and a $8.00 price target for the company. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $10.00.

Shares of Viveve Medical (VIVE) traded down $0.22 during mid-day trading on Thursday, reaching $4.97. The company’s stock had a trading volume of 250,000 shares, compared to its average volume of 138,267. Viveve Medical has a 1-year low of $3.75 and a 1-year high of $11.16. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.89 and a quick ratio of 3.63. The stock has a market cap of $96.55, a price-to-earnings ratio of -2.31 and a beta of -0.67.

Viveve Medical (NASDAQ:VIVE) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.08). Viveve Medical had a negative return on equity of 275.77% and a negative net margin of 257.58%. The business had revenue of $4.07 million during the quarter, compared to analysts’ expectations of $4.10 million. During the same quarter in the previous year, the company posted ($0.46) EPS. The company’s quarterly revenue was up 120.1% on a year-over-year basis. equities analysts anticipate that Viveve Medical will post -2.04 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. HighTower Advisors LLC grew its position in shares of Viveve Medical by 33.2% during the second quarter. HighTower Advisors LLC now owns 1,723,751 shares of the company’s stock valued at $12,379,000 after purchasing an additional 430,033 shares in the last quarter. RTW Investments LP grew its position in shares of Viveve Medical by 18.8% during the third quarter. RTW Investments LP now owns 1,473,028 shares of the company’s stock valued at $7,719,000 after purchasing an additional 233,585 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Viveve Medical by 135.4% during the second quarter. Vanguard Group Inc. now owns 450,142 shares of the company’s stock valued at $3,232,000 after purchasing an additional 258,912 shares in the last quarter. Manatuck Hill Partners LLC grew its position in shares of Viveve Medical by 128.6% during the second quarter. Manatuck Hill Partners LLC now owns 400,000 shares of the company’s stock valued at $2,872,000 after purchasing an additional 225,000 shares in the last quarter. Finally, ING Groep NV grew its position in shares of Viveve Medical by 93.7% during the third quarter. ING Groep NV now owns 325,000 shares of the company’s stock valued at $1,703,000 after purchasing an additional 157,200 shares in the last quarter. Hedge funds and other institutional investors own 66.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Viveve Medical (VIVE) Given “Buy” Rating at Ladenburg Thalmann Financial Services” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/05/viveve-medical-vive-given-buy-rating-at-ladenburg-thalmann-financial-services.html.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply